Premium
Paraplegia following intrathecal cytosine arabinoside
Author(s) -
Zighelboim Jacob,
Gale Robert Peter,
Wolff Larry
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197901)43:1<83::aid-cncr2820430112>3.0.co;2-s
Subject(s) - medicine , pleocytosis , paraplegia , cytosine , cerebrospinal fluid , intrathecal , anesthesia , cytarabine , leukemia , gastroenterology , surgery , spinal cord , dna , psychiatry , biology , genetics
Paraplegia following prophylactic intrathecal cytosine arabinoside (Ara‐C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m 2 /d for 5 consecutive days. Cerebrospinal fluid examination prior to the last dosage of cytosine arabinoside revealed a mononuclear pleocytosis and increased protein. The neurological manifestations developed within one week after the last dose of Ara‐C and persisted for over 8 weeks. Administration of intrathecal Ara‐C in the same dose over longer intervals with 3‐5 days between consecutive doses resulted in mild, transient neurological symptoms (paresthesias) in only one of 30 patients so treated.